Targeting macrophage activation for the prevention and treatment of Staphylococcus aureus biofilm infections.
Biofilm infections often lead to significant morbidity due to their chronicity and recalcitrance to antibiotics. We have demonstrated that methicillin-resistant Staphylococcus aureus (MRSA) biofilms can evade macrophage (MΦ) antibacterial effector mechanisms by skewing MΦs toward an alternatively activated M2 phenotype. To overcome this immune evasion, we have used two complementary approaches. In the first, a proinflammatory milieu was elicited by local administration of classically activated M1 MΦs and in the second by treatment with the C5a receptor (CD88) agonist EP67, which invokes MΦ proinflammatory activity. Early administration of M1-activated MΦs or EP67 significantly attenuated biofilm formation in a mouse model of MRSA catheter-associated infection. Several proinflammatory mediators were significantly elevated in biofilm-infected tissues from MΦ- and EP67-treated animals, revealing effective reprogramming of the biofilm environment to a proinflammatory milieu. A requirement for MΦ proinflammatory activity was demonstrated by the fact that transfer of MyD88-deficient MΦs had minimal impact on biofilm growth. Likewise, neutrophil administration had no effect on biofilm formation. Treatment of established biofilm infections with M1-activated MΦs also significantly reduced catheter-associated biofilm burdens compared with antibiotic treatment. Collectively, these results demonstrate that targeting MΦ proinflammatory activity can overcome the local immune inhibitory environment created during biofilm infections and represents a novel therapeutic strategy.
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Mark L
ML
Hanke
Cortney E
CE
Heim
Amanda
A
Angle
Sam D
SD
Sanderson
Tammy
T
Kielian
D000818:Animals; D018441:Biofilms / Q000187:drug effects*; D055499:Catheter-Related Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D002478:Cells, Cultured; D006801:Humans; D057131:Immune Evasion; D007249:Inflammation / Q000139:chemically induced / Q000276:immunology / Q000382:microbiology; D008262:Macrophage Activation / Q000187:drug effects* / Q000276:immunology; D008264:Macrophages / Q000145:classification / Q000276:immunology* / Q000382:microbiology / Q000637:transplantation; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D053594:Myeloid Differentiation Factor 88 / Q000172:deficiency / Q000235:genetics / Q000276:immunology; D009504:Neutrophils / Q000276:immunology / Q000637:transplantation; D009842:Oligopeptides / Q000138:chemical synthesis / Q000494:pharmacology*; D044087:Receptor, Anaphylatoxin C5a / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology; D013203:Staphylococcal Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*
C507780:Myd88 protein, mouse; D053594:Myeloid Differentiation Factor 88; D009842:Oligopeptides; D044087:Receptor, Anaphylatoxin C5a; C579314:tyrosyl-seryl-phenylalanyl-lysyl-aspartyl-methionyl-prolyl-N-methyleucyl-alanyl-arginine